HomeGeneticsConditionAutosomal dominant optic atrophy and cataract
Back to Condition
Autosomal dominant optic atrophy and cataract
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Autosomal dominant optic atrophy and cataract

Autosomal dominant optic atrophy and cataract is an eye disorder characterized by progressive vision loss and lens clouding, often caused by mitochondrial dysfunction.

Overview

This disorder is characterized by impaired vision, which can range from nearly normal to complete blindness. While most affected individuals experience decreased visual acuity from birth, others may notice symptoms in early childhood or later. Both eyes are typically affected equally.

Symptoms

Vision impairment is caused by several factors:

  • Retinal ganglion cell loss: A progressive loss of light-sensitive cells in the retina.
  • Optic nerve atrophy: Degeneration of the nerves that relay visual information to the brain, often appearing as a pale color (pallor) during eye exams.
  • Cataracts: Clouding of the eye lenses, typically appearing in childhood.
  • Other eye problems: Involuntary eye movements (nystagmus) and color vision deficiency (difficulty distinguishing blue and green).
  • Neurological symptoms: Some individuals experience balance and coordination problems (cerebellar ataxia), gait issues, tingling sensations (paresthesias), muscle stiffness (spasticity), tremors, or sensorineural deafness.

Causes

The condition is caused by mutations in the OPA3 gene. The OPA3 protein is located within mitochondria, the energy-producing centers of cells. While its exact function is not fully understood, it is believed to help organize mitochondrial structure and regulate controlled cell death (apoptosis).

Mutations lead to disorganized, poorly functioning mitochondria with reduced energy production. Cells with high energy demands, such as retinal ganglion cells, are particularly susceptible to premature death. When these cells die, the optic nerves atrophy and cannot transmit visual information to the brain. It is believed that similar mitochondrial dysfunction in other nerve cells leads to the neurological symptoms observed in some patients.

Inheritance

This condition is inherited in an autosomal dominant pattern, meaning one copy of the altered gene in each cell is sufficient to cause the disorder. In most cases, an affected person has one parent with the condition.

Frequently Asked Questions

Cataract extraction is generally safe and often improves visual acuity dramatically. Pre‑operative assessment should include a cardiac evaluation because some patients have associated cardiomyopathy. Intra‑operatively, surgeons may use lower phaco energy settings to reduce oxidative stress on already compromised mitochondria. Post‑operative anti‑inflammatory regimens should avoid prolonged high‑dose steroids, which can exacerbate mitochondrial dysfunction; a short taper of topical steroids is preferred.
Currently, no disease‑modifying treatment is approved. However, mitochondrial‑supportive supplements such as coenzyme Q10, riboflavin, and L‑carnitine are sometimes used off‑label, though evidence is limited. The most effective strategy is early detection and prompt cataract removal to maximize the remaining visual potential while the optic nerve is still functional.
Patients should have a baseline neurological exam, audiogram, and gait assessment by age 5. Follow‑up every 1–2 years includes: (1) formal vestibular testing if balance problems arise, (2) nerve conduction studies if peripheral neuropathy is suspected, and (3) MRI of the brain if new ataxia, tremor, or spasticity develops. Early physiotherapy and occupational therapy can mitigate functional decline.
detailed eye exam is essential. Slit‑lamp examination will reveal lens opacity characteristic of cataract, while funduscopy shows a pale, thin optic disc typical of optic atrophy. Optical coherence tomography (OCT) can quantify retinal nerve‑fiber layer thinning, confirming optic nerve loss even when a cataract is present. Visual‑evoked potentials (VEP) are also helpful; markedly reduced amplitudes suggest optic pathway dysfunction independent of lens clarity.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

kontakt@hittavard.se

Ⓒ 2024. Alla rättigheter förbehålls av juxt ab